Orforglipron — Safety, Research, Risks & Legal Status

Not medical advice. Orforglipron is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	MK-0941, GIP agonist
Category	Research Chemical
phase_stage	Phase 2 (halted)
developer	Merck
development_status	discontinued
year_halted	2018
US legal status	Investigational drug (Merck). Halted after Phase 2. No current regulatory path to approval in USA. May be available in clinical trials in select jurisdictions.

What is Orforglipron?

A selective GIP (glucose-dependent insulinotropic peptide, formerly known as gastric inhibitory peptide) receptor agonist. Works via the GIP pathway alone (not GLP-1), to stimulate insulin secretion and potentially increase energy expenditure.

How it works

Orforglipron selectively activates GIP receptors on pancreatic beta-cells and adipose tissue. Stimulates glucose-dependent insulin secretion and may increase energy expenditure via brown adipose tissue activation, but mechanism is less established than GLP-1 pathway.

Background & history

Developed by Merck as selective GIP agonist for diabetes. Phase 2 trials conducted ~2015-2018. Development halted due to modest efficacy relative to emerging GLP-1/GIP dual agents (tirzepatide).

What the research says

Phase 2 trial showed modest effects on glucose control and weight change (weight loss was not a primary benefit relative to GLP-1 or dual agents). Development halted; mechanism less well-validated than GLP-1 or dual GLP-1/GIP approaches. Limited human evidence.

Reported effects

Studied for improved glucose control via GIP-mediated insulin secretion
Reported modest metabolic effects in Phase 2
Research suggests potential energy expenditure effects (preclinical)
Limited evidence for weight loss compared to GLP-1 agents
May support beta-cell function preservation
Possible anti-inflammatory effects (preclinical)

Dosing & administration (informational)

Phase 2 trials used oral dosing. No final dose established; development discontinued before Phase 3.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Safety data limited to Phase 2 small trials
Potential hypoglycemia if used in insulin-treated diabetes
GI side effects possible (nausea, vomiting)
Long-term safety not established
Immunogenicity risk with repeated dosing
Development halted; safety profile incomplete

Drug & supplement interactions

Insulin or sulfonylureas: potential hypoglycemia risk
Other incretin-based drugs (DPP-4 inhibitors): mechanism overlap
Oral medications: possible absorption changes
Cardiovascular drugs: limited interaction data available
No current drug-interaction database (development halted)

Who should avoid it

Development halted; not recommended for any use outside historical trials
Uncontrolled hypoglycemia
Severe kidney or liver impairment
Pregnancy (insufficient safety data)
Known allergy to GIP agonists or incretin agents

How it is commonly combined

Orforglipron development is halted; no current stacking data or recommendations. Not combined with active-development GLP-1/GIP dual agents.

Legal & regulatory. Investigational drug (Merck). Halted after Phase 2. No current regulatory path to approval in USA. May be available in clinical trials in select jurisdictions.

Quality & harm reduction

N
o
c
o
m
m
e
r
c
i
a
l
p
r
o
d
u
c
t
;
c
l
i
n
i
c
a
l
-
t
r
i
a
l
a
c
c
e
s
s
o
n
l
y
o
r
h
a
l
t
e
d
.
R
e
s
e
a
r
c
h
-
c
h
e
m
i
c
a
l
s
o
u
r
c
i
n
g
w
o
u
l
d
b
e
u
n
v
e
r
i
f
i
e
d
a
n
d
u
n
r
e
g
u
l
a
t
e
d
;
n
o
m
a
n
u
f
a
c
t
u
r
i
n
g
s
t
a
n
d
a
r
d
s
e
s
t
a
b
l
i
s
h
e
d
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Why was orforglipron halted?

Merck discontinued development; likely due to modest efficacy relative to GLP-1 agents and lack of compelling competitive advantage.

Is GIP alone as good as dual GLP-1/GIP?

No. Dual agents (tirzepatide) outperformed single GIP in trials. GIP monotherapy shows weaker effects on weight and glucose.

Can I still get orforglipron?

No. Development is halted; not available commercially or in active trials. Historical trial data only.

Why did GLP-1/GIP dual agents work better?

Dual mechanisms target multiple pathways simultaneously. GLP-1 provides appetite suppression and GLP-1 receptor-mediated insulin secretion; GIP adds energy expenditure. Single GIP lacked sufficient appetite reduction.

References & further reading

Merck Phase 2 trial results and press releases
GIP-receptor agonist mechanism reviews
Comparative failure analysis vs tirzepatide efficacy
Published Phase 2 safety and efficacy endpoints